Revium Rx.
Revium Rx is a U.S.-based pre-clinical biopharmaceutical company focused on developing nano-medicine and lipid-based drug delivery platforms. Its pipeline includes programs aimed at hard-to-treat diseases such as antimicrobial resistance and solid tumors, with development activities centered on encapsulated therapeutics and controlled-release delivery.
Fiscal year 2025 · change from previous year
Development 2025–2025
Business
Share of revenuePreclinical therapeutic candidates built on nano-liposomal and lipid-based delivery systems.
Lipid-based platform work intended to support prophylactic and vaccine applications.
Internal development, regulatory preparation, and manufacturing-readiness activities.
Customers
Revium Rx does not currently sell commercial products; its near-term counterparties are research collaborators, contract manufacturers, clinical and preclinical service providers, and potential licensing or strategic partners. If its programs advance, the eventual customers would be hospitals, physicians, and patients through approved pharmaceutical products, but the present business is centered on development rather than sales. The company’s work is also shaped by academic and technology-transfer relationships, including rights and obligations tied to external scientific collaborators.
Academic and technology-transfer partners that provide scientific rights, data, or platform access for candidate development.
Third-party labs and manufacturers that support formulation, preclinical testing, and GMP preparation.
Pharmaceutical or biotech partners that may fund, license, or co-develop programs after proof-of-concept.
Patients with unmet-needs indications such as antimicrobial resistance or solid tumors, if products are approved.
Strategy
The company’s stated priority is to advance its Nano-Mupirocin program toward initial clinical development while resolving scientific and contractual issues affecting other programs. It is also working to preserve optionality across its lipid-based platforms so that one or more candidates can progress into proof-of-concept and partnering discussions. In a preclinical biotech model, this strategy matters because value creation depends on generating enough data to attract capital, collaborators, or licensing interest.
This is the most advanced disclosed program and the clearest path to generating value and external interest.
Program progress depends on clearing the scientific-report dispute and restarting the planned safety study.
Positive study results would support platform credibility, patent strategy, and future partnering.
Geography
Revium Rx is incorporated in the United States and operates as a U.S.-based public biopharmaceutical company. Its disclosed development history includes a wholly owned subsidiary in Israel, reflecting reliance on cross-border scientific and intellectual-property relationships. Because the company is pre-commercial, geography matters mainly through where research rights, collaborators, and development services are located rather than through product sales.
Risks
Revium Rx faces the typical risks of a preclinical biotech company: scientific failure, regulatory delay, and dependence on external funding before any product revenue exists. Company-specific risks include unresolved collaborator issues, delayed studies, and going-concern uncertainty, all of which can slow or stop pipeline advancement. Because the business is concentrated in a small number of early-stage programs, setbacks in one program can have an outsized effect on the company’s prospects.
The company depends on external capital to fund R&D and may need to reduce or delay programs if financing is unavailable.
Exposure: All development programs
The planned safety study is on hold pending resolution of a scientific-report and option-exercise disagreement with Yissum.
Exposure: Nano-Candesartan program
Early-stage drug candidates may not demonstrate safety, efficacy, or manufacturability needed for clinical advancement.
Exposure: All pipeline candidates
The SARS-CoV-2 challenge study has not produced results, delaying proof-of-concept validation and patent strategy work.
Exposure: LPLT platform
Accounting
Judgemental itemsPreclinical study delays and pauses change when external service costs are recognized, affecting quarterly comparability.
Impact: R&D spending and operating loss
Management has concluded there is substantial doubt about continued operations absent additional capital.
Impact: Financial statement disclosures and liquidity analysis
Disputes over scientific reports or option rights can create uncertain obligations or affect program access.
Impact: Potential liabilities and program rights
If programs do not advance, any capitalized development-related amounts or related rights may require impairment review.
Impact: Balance sheet carrying values
Similar listed companies
Publicly listed companies with a comparable business focus.
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Citius Pharmaceuticals, Inc.
CTXR · Pharmaceutical Preparations
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Iterum Therapeutics plc
ITRMF · Pharmaceutical Preparations
Iterum Therapeutics plc is a biopharmaceutical company focused on developing and commercializing ORLYNVAH™ (sulopenem etzadroxil and probenecid), an oral…
Last updated: 16/06/2026